home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
  HUM-MOLGEN -> Genetic News | search  

RNA Trojan Horses Zero In On Liver Cirrhosis

  April, 3 2008 8:51
your information resource in human molecular genetics

Using vitamin A to target the cells that cause liver cirrhosis may improve the treatment of the disease, according to research reported online in Nature Biotechnology.

Cirrhosis, which affects hundreds of millions of people worldwide, is a scarring response to liver damage, which is most commonly inflicted by hepatitis infection, alcohol abuse or nutritional deficiencies. It occurs when specialized liver cells called stellate cells are triggered to produce collagen, the fibrous material that toughens skin and tendons. There are no approved antifibrotic therapies, partly due to the difficulty in specifically targeting collagen-producing cells to avoid unwanted side effects on healthy tissue.

Yoshiro Niitsu and colleagues exploit two properties of liver stellate cells -- their ability to take up vitamin A and to make collagen. First, they designed small interfering RNA molecules (siRNAs) that block a key protein in collagen synthesis. Then, by packaging the siRNAs in carriers coated with vitamin A, they tricked the stellate cells into letting in the inhibitor, which shut down collagen secretion.

The treatment rescued rats from cirrhosis induced by three different approaches. As relatives of liver stellate cells contribute to fibrosis in organs, such as the pancreas and kidney, this type of siRNA therapy might be extended to reverse other fibrotic conditions.

Author contact:

Yoshiro Niitsu (Sapporo Medical University School of Medicine, Hokkaido, Japan)
E-mail: niitsu@sapmed.ac.jp

Abstract available online.

(C) Nature Biotechnology press release.

Message posted by: Trevor M. D'Souza

print this article mail this article
Latest News
Variants Associated with Pediatric Allergic Disorder

Mutations in PHF6 Found in T-Cell Leukemia

Genetic Risk Variant for Urinary Bladder Cancer

Antibody Has Therapeutic Effect on Mice with ALS

Regulating P53 Activity in Cancer Cells

Anti-RNA Therapy Counters Breast Cancer Spread

Mitochondrial DNA Diversity

The Power of RNA Sequencing

‘Pro-Ageing' Therapy for Cancer?

Niche Genetics Influence Leukaemia

Molecular Biology: Clinical Promise for RNA Interference

Chemoprevention Cocktail for Colon Cancer

more news ...

Generated by News Editor 2.0 by Kai Garlipp
WWW: Kai Garlipp, Frank S. Zollmann.
7.0 © 1995-2023 HUM-MOLGEN. All rights reserved. Liability, Copyright and Imprint.